VANDA PHARMACEUTICALS INC (VNDA) Stock Fundamental Analysis
USA - NASDAQ:VNDA - US9216591084 - Common Stock
4.32 USD
-1.09 (-20.15%)
4.5 USD
+0.18 (+4.17%)
Overall VNDA gets a fundamental rating of 2 out of 10. We evaluated VNDA against 534 industry peers in the Biotechnology industry. While VNDA is still in line with the averages on profitability rating, there are concerns on its financial health. VNDA has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
VNDA had negative earnings in the past year.
In the past year VNDA has reported a negative cash flow from operations.
Of the past 5 years VNDA 4 years were profitable.
Of the past 5 years VNDA 4 years had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of -10.71%, VNDA belongs to the best of the industry, outperforming 83.33% of the companies in the same industry.
VNDA has a better Return On Equity (-13.76%) than 87.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.71% | ||
| ROE | -13.76% | ||
| ROIC | N/A |
ROA(3y)-0.5%
ROA(5y)1.69%
ROE(3y)-0.62%
ROE(5y)1.97%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
VNDA has a Gross Margin of 94.40%. This is amongst the best in the industry. VNDA outperforms 94.01% of its industry peers.
VNDA's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for VNDA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 94.4% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.39%
GM growth 5Y1.12%
2. Health
2.1 Basic Checks
VNDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VNDA has more shares outstanding
VNDA has more shares outstanding than it did 5 years ago.
The debt/assets ratio for VNDA is higher compared to a year ago.
2.2 Solvency
VNDA has an Altman-Z score of 1.19. This is a bad value and indicates that VNDA is not financially healthy and even has some risk of bankruptcy.
VNDA has a Altman-Z score of 1.19. This is in the better half of the industry: VNDA outperforms 62.36% of its industry peers.
VNDA has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of VNDA (0.01) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.19 |
ROIC/WACCN/A
WACC8.67%
2.3 Liquidity
A Current Ratio of 3.25 indicates that VNDA has no problem at all paying its short term obligations.
VNDA's Current ratio of 3.25 is on the low side compared to the rest of the industry. VNDA is outperformed by 61.24% of its industry peers.
VNDA has a Quick Ratio of 3.23. This indicates that VNDA is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.23, VNDA perfoms like the industry average, outperforming 40.64% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.25 | ||
| Quick Ratio | 3.23 |
3. Growth
3.1 Past
The earnings per share for VNDA have decreased strongly by -407.14% in the last year.
Looking at the last year, VNDA shows a small growth in Revenue. The Revenue has grown by 3.18% in the last year.
Measured over the past years, VNDA shows a decrease in Revenue. The Revenue has been decreasing by -2.64% on average per year.
EPS 1Y (TTM)-407.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-322.22%
Revenue 1Y (TTM)3.18%
Revenue growth 3Y-9.56%
Revenue growth 5Y-2.64%
Sales Q2Q%18.07%
3.2 Future
VNDA is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.83% yearly.
The Revenue is expected to grow by 1.13% on average over the next years.
EPS Next Y-475.88%
EPS Next 2Y-82.36%
EPS Next 3Y6.83%
EPS Next 5YN/A
Revenue Next Year12.81%
Revenue Next 2Y24.69%
Revenue Next 3Y26.56%
Revenue Next 5Y1.13%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
VNDA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VNDA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-82.36%
EPS Next 3Y6.83%
5. Dividend
5.1 Amount
No dividends for VNDA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
4.32
-1.09 (-20.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners79.02%
Inst Owner Change-0.34%
Ins Owners7.03%
Ins Owner Change6.65%
Market Cap255.27M
Revenue(TTM)198.77M
Net Income(TTM)-66937000
Analysts80
Price Target12.92 (199.07%)
Short Float %6.97%
Short Ratio7.9
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.3%
Min EPS beat(2)-26.44%
Max EPS beat(2)17.84%
EPS beat(4)3
Avg EPS beat(4)15.96%
Min EPS beat(4)-26.44%
Max EPS beat(4)45.98%
EPS beat(8)6
Avg EPS beat(8)5.71%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)1.57%
Min Revenue beat(2)-5.56%
Max Revenue beat(2)8.7%
Revenue beat(4)1
Avg Revenue beat(4)-0.51%
Min Revenue beat(4)-5.56%
Max Revenue beat(4)8.7%
Revenue beat(8)3
Avg Revenue beat(8)0.35%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-34.65%
EPS NY rev (1m)0%
EPS NY rev (3m)-20.98%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.12%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.25 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.52 | ||
| P/tB | 0.68 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.42
EYN/A
EPS(NY)-1.06
Fwd EYN/A
FCF(TTM)-1.12
FCFYN/A
OCF(TTM)-1.1
OCFYN/A
SpS3.44
BVpS8.23
TBVpS6.36
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.71% | ||
| ROE | -13.76% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 94.4% | ||
| FCFM | N/A |
ROA(3y)-0.5%
ROA(5y)1.69%
ROE(3y)-0.62%
ROE(5y)1.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.39%
GM growth 5Y1.12%
F-Score3
Asset Turnover0.33
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 13.98% | ||
| Cap/Sales | 0.55% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.25 | ||
| Quick Ratio | 3.23 | ||
| Altman-Z | 1.19 |
F-Score3
WACC8.67%
ROIC/WACCN/A
Cap/Depr(3y)14.89%
Cap/Depr(5y)25.49%
Cap/Sales(3y)0.24%
Cap/Sales(5y)0.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-407.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-322.22%
EPS Next Y-475.88%
EPS Next 2Y-82.36%
EPS Next 3Y6.83%
EPS Next 5YN/A
Revenue 1Y (TTM)3.18%
Revenue growth 3Y-9.56%
Revenue growth 5Y-2.64%
Sales Q2Q%18.07%
Revenue Next Year12.81%
Revenue Next 2Y24.69%
Revenue Next 3Y26.56%
Revenue Next 5Y1.13%
EBIT growth 1Y-210.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year7.55%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-263.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-258.43%
OCF growth 3YN/A
OCF growth 5YN/A
VANDA PHARMACEUTICALS INC / VNDA FAQ
What is the ChartMill fundamental rating of VANDA PHARMACEUTICALS INC (VNDA) stock?
ChartMill assigns a fundamental rating of 2 / 10 to VNDA.
Can you provide the valuation status for VANDA PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 0 / 10 to VANDA PHARMACEUTICALS INC (VNDA). This can be considered as Overvalued.
What is the profitability of VNDA stock?
VANDA PHARMACEUTICALS INC (VNDA) has a profitability rating of 4 / 10.
What is the earnings growth outlook for VANDA PHARMACEUTICALS INC?
The Earnings per Share (EPS) of VANDA PHARMACEUTICALS INC (VNDA) is expected to decline by -475.88% in the next year.